Protease-activated receptor (PAR) 2 is abundantly expressed by bronchial smooth muscle and epithelial cells (Schmidlin et al., 2001 ). Activation of epithelial PAR 2 promotes the generation and release of a variety of cytokines and mediators, including prostaglandin (PG) E 2 (Lan et al., 2001; Asokananthan et al., 2002; Kawabata et al., 2004a) . PAR 2 -mediated production of PGE 2 occurs via the nontranscriptional activation of enzymes involved in PGE 2 synthesis, including cyclooxygenase (COX) and prostaglandin E synthase (PGES) (Kawabata et al., 2004a) . Of particular interest, PAR 2 is one of only a small number of receptor subtypes that have been shown to be linked to the rapid generation of epithelial PGE 2 , which has many beneficial actions in the airways (for review, see Vancheri et al., 2004) . Epithelialderived PGE 2 is released toward submucosal structures (Perng et al., 2003) , where it can activate prostanoid (EP) receptors and produce a range of beneficial effects, including bronchodilatation and suppression of the function of mast cells, eosinophils, and fibroblasts. Consistent with this, exogenous application of PGE 2 inhibited allergen-induced inflammation and bronchoconstriction in human asthmatic subjects (Gauvreau et al., 1999) and in animal models of allergic airways inflammation (De Campo and Henry, 2005) . Likewise, strategies that suppress the production of PGE 2 , such as the administration of drugs that inhibit COX and the use of COX Ϫ/Ϫ mice, were associated with worsening allergic inflammation (Carey et al., 2003) and fibrotic disease (Hodges et al., 2004) . PAR 2 activators such as SLIGRL-NH 2 produced bronchoprotective effects in a murine model of allergic inflammation via COX-dependent mechanisms (De Campo and Henry, 2005) .
Glucocorticoids are used widely to suppress airways inflammation in people with persistent asthma and are likely to continue to be the cornerstone of asthma therapy for the foreseeable future. Indeed, the central importance of glucocorticoids in the management of persistent asthma is highlighted by the fact that other pharmacotherapies, such as long-acting ␤-adrenoceptor agonists and leukotriene receptor antagonists, are typically coadministered with glucocorticoids rather than used alone. Glucocorticoids have been shown to significantly reduce PGE 2 levels in airway cells via a range of genomic and nongenomic actions; for example, by inhibiting the expression of PGES and COX (Mitchell et al., 1994; Newton et al., 1997; Chivers et al., 2004) and suppressing the release of arachidonic acid, an initial substrate in the synthesis of PGE 2 (Chivers et al., 2004) . Glucocorticoids may also reduce the levels of PGE 2 by increasing the expression of prostaglandin dehydrogenase, the principal enzyme responsible for metabolizing PGE 2 (Tong and Tai, 2005) . Consistent with this, it has been shown that neutrophil elastase-induced production of PGE 2 in human airway epithelial cells, perhaps mediated via PAR 2 , was abolished by glucocorticoids (Perng et al., 2003) . However, glucocorticoid-induced suppression of PGE 2 levels has been observed almost exclusively in cell culture systems, which may not directly reflect the situation in intact tissue and whole animal systems. Thus, the aim of the current study was to determine whether potential bronchoprotective effects produced by PAR 2 activators, such as PGE 2 production, airway smooth muscle relaxation, and anti-inflammatory effects were modulated in cells, tissues, and animals exposed to glucocorticoids. A series of studies were conducted in cultured A549 cells, cultured mouse tracheal segments, or BALB/c mice that had been pretreated with dexamethasone (in the presence and absence of a proinflammatory stimulus, bacterial lipopolysaccharide (LPS) before determining their responsiveness to the PAR 2 activators SLIGRL-NH 2 and f-LIGRL-NH 2 ).
Materials and Methods
Cell Culture Studies Using A549 Cells. A549 cells were cultured in F12-K medium with 5% fetal calf serum, 2 mM glutamine, and gentamicin (100 g/ml) at 37°C with 5% CO 2 /95% air in 24-well plates to 80% confluency, stabilized in serum-free medium overnight, and then exposed to combinations of selected agents in serum-free medium. In initial experiments, A549 cells were exposed to the PAR 2 -activating peptide SLIGRL-NH 2 (or a partially scrambled control peptide, LSIGRL) at different concentrations (1-100 M) for different periods of time (0.25-24 h), and the medium was collected and stored at Ϫ80°C for subsequent determination of PGE 2 levels. In other experiments, cells were preincubated with dexamethasone (1 M or cyclodextrin vehicle) in the presence or absence of a proinflammatory stimuli (10 g/ml lipopolysaccharide or saline vehicle) for 24 h, washed in serumfree medium, and stimulated with 50 M SLIGRL-NH 2 for a further 30 min, at which time the medium was collected and stored for PGE 2 assay. Aliquots of medium were assayed for PGE 2 using a commercial enzyme immunoassay kit (Cayman Chemical, Ann Arbor, MI) following the manufacturer's instructions.
Isometric Tension Recording Studies Using Mouse Isolated Tracheal Segments. Male BALB/c mice (specified pathogen free) at 8 to 10 weeks of age (Animal Resources Centre, Perth, Australia) were maintained in a 12-h light/dark cycle and received autoclaved rodent food pellets and acidified water ad libitum. All studies were conducted with the approval of the University of Western Australia's Animal Ethics Committee. Mice were killed by lethal injection (250 mg/kg pentobarbitone sodium i.p.), and the trachea were harvested.
Segments of mouse trachea were suspended between two stainless steel hooks at a resting tension of 0.4 g in a tissue bath containing 2 ml of Krebs-bicarbonate solution, maintained at 37°C, and bubbled with 5% CO 2 in O 2 . The composition of Krebs-bicarbonate solution was: 117 mM NaCl, 5.36 mM KCl, 25 mM NaHCO 3 , 1.03 mM KH 2 PO 4 , 0.57 mM MgSO 4 .7H 2 O, 2.5 mM CaCl 2 , and 11.1 mM Dglucose. The lower hook was attached to a micrometer driven anchor in the bath, and the upper hook was attached to a force-displacement transducer (model FT03C; Grass Instruments, West Warwick, RI) coupled to a PowerLab system (ADInstruments Pty Ltd., Bella Vista, Australia). Tracheal preparations were washed regularly for 30 min, and the tension was periodically readjusted to 0.4 g. On two consecutive occasions separated by a 15-min washout period, preparations were exposed to cumulatively administered doses of carbachol (0.2 and 10 M). After a further 20-min washout period, a cumulative concentration-response curve was constructed for carbachol (0.03-10 M). To assess PAR 2 -mediated relaxation responses, tracheal preparations were precontracted with 1 M carbachol (producing approximately 60% of the contractile response obtained by 10 M carbachol), and upon reaching a plateau level of contraction, a single 2 M concentration of SLIGRL-NH 2 was added for 5 min, during which time a peak relaxation response was obtained. The preparation was washed with drug-free Krebs-bicarbonate solution and re-equilibrated for 20 min before the cycle was repeated a further three times to determine the relaxant responses to 5, 10, and 20 M SLIGRL-NH 2 . A cumulative concentration-response curve was then constructed to exogenous PGE 2 (3-3000 nM) in preparations also precontracted with 1 M carbachol. In these studies, tissues were exposed to 1 M dexamethasone (or cyclodextrin vehicle) for 15 min before each carbachol-induced contraction and retained in the bath until the response to carbachol, SLIGRL-NH 2 , or PGE 2 had been obtained (short-term in vitro dexamethasone exposure). In all cases, the level of relaxation response was calculated as a percentage of the level of precontraction, such that 100% relaxation represents a complete reversal of the carbachol-induced precontraction.
Tissue Culture Studies Using Mouse Isolated Tracheal Segments. In a separate series of experiments, mouse isolated tracheal segments were cultured using the method of Bachar et al. (2005) . In brief, tracheal segments obtained from BALB/c mice as described above were cultured in Dulbecco's modified Eagle's medium, supplemented with 100 U/ml penicillin and 100 g/ml streptomycin, at 37°C with 5% CO 2 /95% air for 3 days. During the 3 days of organ culture, tracheal segments were exposed to dexamethasone (1 M, or cyclodextrin vehicle) and transferred daily to a new well containing fresh media and dexamethasone (long-term in vitro exposure to dexamethasone). After organ culture, tracheal segments were transferred to tissue baths and isometric tension recording studies completed, as described above.
Whole-Animal Studies Using BALB/c Mice. As an extension of the studies described above in which tracheal segments were exposed to dexamethasone in vitro, male BALB/c mice were given dexamethasone in vivo (3 mg/kg or cyclodextrin vehicle i.p.). Twentyfour hours later, mice were sacrificed, and their trachea were removed and used in isometric tension recording studies (in vivo exposure to dexamethasone). The influence of in vivo pretreatment with dexamethasone (3 mg/kg or cyclodextrin vehicle i.p.) on subsequent in vitro responsiveness to carbachol, SLIGRL-NH 2 , and PGE 2 was also determined in mice that were exposed to the proinflammatory stimulus lipopolysaccharide at the time of dexamethasone administration. Lipopolysaccharide (10 g in 20 l of sterile saline) was administered intranasally by applying the aliquot to the external nares of mice that had been anesthetized with methoxyflurane.
PAR 2 activators such as SLIGRL-NH 2 have previously been reported to inhibit bacterial lipopolysaccharide-induced recruitment of polymorphonuclear leukocytes into the airways of BALB/c mice (Moffatt et al., 2002) . A final series of studies was conducted to determine whether this effect was modulated by dexamethasone. Mice were pretreated for 3 days with daily injections of dexamethasone (1 mg/kg or cyclodextrin vehicle i.p.), and then inoculated intranasally with a 20-l solution containing combinations of lipopolysaccharide (10 g), a PAR 2 -activating peptide, f-LIGRL-NH 2 (30 g), and PGE 2 (10 g). Three hours later, groups of mice were sacrificed as described above, the trachea were cannulated, and bronchoalveolar
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at ASPET Journals on October 18, 2017 jpet.aspetjournals.org Downloaded from lavage (BAL) was performed by intratracheal instillation of 2.5 ml of cold phosphate-buffered saline in 0.5-ml aliquots. Recovered BAL fluid was centrifuged at 400g for 5 min, and the cell pellet was resuspended in 1.0 ml of mouse phosphate-buffered saline containing 1% bovine serum albumin. Total BAL cell counts were determined (Naubauer hemocytometer), and cytospin preparations were generated (Shandon Scientific Cytocentrifuge; Thermo Electron Corporation, Waltham, MA) and stained with Rapid I/II (Amber Scientific, WA, Australia). Differential cell counts were conducted, with macrophages, neutrophils, lymphocytes, and eosinophils identified using standard morphologic criteria.
Reagents. Water-soluble dexamethasone and its carrier (2-hydroxypropyl)-␤-cyclodextrin were purchased from Sigma-Aldrich (St. Louis, MO), as were carbachol, lipopolysaccharide (Escherichia coli strain 0127:B8), and PGE 2 . The PAR 2 peptides SLIGRL-NH 2 , LSI-GRL-NH 2 , and f-LIGRL-NH 2 were synthesized by Proteomics International (Perth, Australia). All cell culture reagents were obtained from Invitrogen (Carlsbad, CA).
Data Analyses. Estimates of EC 50 values were obtained by fitting each PGE 2 and carbachol concentration-response curve to a fourparameter logistic function (sigmoidal curve, SigmaPlot; Systat Software, Inc., San Jose, CA). Estimates of SLIGRL-NH 2 potency were determined by estimating the concentration of SLIGRL-NH 2 that produced 30% relaxation of the carbachol-induced contraction. Group agonist potency data (presented in Table 1 ) are expressed as mean and 95% confidence limits, and different groups were compared using analysis of variance on log-transformed data. Data in the figures are presented as mean Ϯ S.E.M. Statistically significant differences were indicated when the P value was less than 0.05.
Results

Influence of Lipopolysaccharide and Dexamethasone on SLIGRL-NH 2 -Induced Generation of PGE 2 in A549 Cell Cultures
The PAR 2 -activating peptide SLIGRL-NH 2 produced timeand concentration-dependent increases in PGE 2 levels in the culture medium of A549 cells (Fig. 1) . Increases in PGE 2 levels were rapid, and within 15 min of exposure to SLIGRL-NH 2 , the levels of PGE 2 were nearly half of the maximum levels obtained at 24 h (Fig. 1A) . The concentration of SLI-GRL-NH 2 that produced 50% of the maximum increase in PGE 2 levels (EC 50 value) was approximately 35 M (Fig. 1B) . As expected, SLIGRL-NH 2 -induced increases in PGE 2 levels were abolished by a cyclooxygenase inhibitor indomethacin, and the partially scrambled control peptide LSIGRL-NH 2 produced negligible increases in PGE 2 levels in A549 cell cultures (Fig. 1) .
As shown in Fig. 2 , A549 cell cultures exposed to 50 M SLIGRL-NH 2 for 30 min had significantly elevated levels of PGE 2 (P Ͻ 0.05 compared with no SLIGRL-NH 2 ). These acute SLIGRL-NH 2 -induced increases in PGE 2 levels were further enhanced in A549 cell cultures that had been preexposed for 24 h to 10 g/ml lipopolysaccharide (P ϭ 0.001 compared with SLIGRL-NH 2 alone, Fig. 2 ). In contrast, acute SLIGRL-NH 2 -induced increases in PGE 2 levels were not evident in A549 cells that had been pre-exposed to dexamethasone (Fig. 2) , irrespective of whether the cells had been coexposed to lipopolysaccharide.
Influence of Dexamethasone on SLIGRL-NH 2 -and PGE 2 -Induced Relaxation Responses in Mouse Isolated Tracheal Preparations
Short-Term in Vitro Exposure to Dexamethasone. Both SLIGRL-NH 2 and PGE 2 produced concentration-dependent relaxation responses in mouse isolated tracheal preparations precontracted with 1 M carbachol (Fig. 3, A and B) . Short-term in vitro exposure to dexamethasone (1 M for 15 min) had no significant inhibitory effect on either the potency or maximum relaxation response obtained to SLIGRL-NH 2 or PGE 2 (Fig. 3 , A and B; Table 1 ). The muscarinic cholinoceptor agonist carbachol induced concentration-dependent contractions, and these responses were similar in tracheal preparations pre-exposed for 15 min to 1 M dexamethasone ( Fig. 3C ; Table 1 ).
Longer Term in Vitro Exposure to Dexamethasone. To determine the influence of longer periods of in vitro dexamethasone exposure, experiments were conducted using mouse isolated tracheal segments maintained for 3 days in tissue culture media. The tissue culture process per se did not significantly affect the potencies and maximum relaxation responses of SLIGRL-NH 2 , PGE 2 , and carbachol; contraction and relaxation responses obtained in preparations after 3 days in culture ( Fig. 4 ; Table 1) were not significantly different to responses previously obtained in fresh preparations ( Fig. 3; Table 1 ). The inclusion of 1 M dexamethasone in the tissue media for 3 days also had no significant effect on relaxation responses obtained to either SLIGRL-NH 2 or PGE 2 (Fig. 4, A and B vitro exposure to 1 M dexamethasone was not associated with any significant change in carbachol potency ( Fig. 4C ; Table 1 ).
In Vivo Exposure to Dexamethasone. In vitro responsiveness to carbachol, SLIGRL-NH 2 , and PGE 2 was also determined in tracheal preparations obtained from mice that had been given an i.p. injection of 3 mg/kg dexamethasone (or vehicle) 24 h before tracheal resection. As shown in Fig. 5 , in vitro responsiveness to SLIGRL-NH 2 , PGE 2 , and carbachol determined in tracheal preparations obtained from dexamethasone-treated mice was similar to that in preparations from vehicle-treated mice ( Fig. 5; Table 1 ). Likewise, in mice exposed to lipopolysaccharide, in vivo administration of dexamethasone did not modulate the in vitro responsiveness of tracheal preparations to SLIGRL-NH 2 , PGE 2 or carbachol ( Fig. 6 ; Table 1 ).
Influence of Dexamethasone on f-LIGRL-NH 2 -Induced Inhibition of Lipopolysaccharide-Induced BAL Neutrophilia in BALB/c Mice. As expected, intranasal administration of lipopolysaccharide induced a marked inflammatory response in mice, characterized by the appearance of large numbers of neutrophils in BAL fluid (Fig. 7A) . The numbers of neutrophils were significantly lower in BAL fluid recovered from lipopolysaccharide-exposed mice that had been treated with either the PAR 2 -activating peptide f-LIGRL-NH 2 (50 Ϯ 11% fewer neutrophils, n ϭ 6, P Ͻ 0.001) or dexamethasone (60 Ϯ 3% fewer neutrophils, n ϭ 6, P Ͻ 0.001) (Fig. 7A) . Of particular interest, even fewer BAL neutrophils were obtained from lipopolysaccharide-exposed mice that received both f-LIGRL-NH 2 and dexamethasone (80 Ϯ 7% fewer neutrophils, P ϭ 0.01 compared with lipopolysaccharide-exposed mice that received either f-LIGRL-NH 2 or dexamethasone alone) (Fig. 7A) . A similar profile of response was observed in mice that received PGE 2 instead of f-LIGRL-NH 2 (Fig. 7B) . That is, the numbers of BAL neutrophils recovered from lipopolysaccharide-exposed mice were reduced by 54 Ϯ 5% with PGE 2 alone (n ϭ 7), by 40 Ϯ 5% with dexamethasone alone (n ϭ 7), and by 83 Ϯ 3% with PGE 2 plus dexamethasone (n ϭ 8, P ϭ 0.005, Fig. 7B ).
Discussion
There is a large body of compelling data indicating that airway epithelial cell cultures exposed to glucocorticoids have suppressed PGE 2 levels (Mitchell et al., 1994; Newton et al., Fig. 1 . Levels of PGE 2 in the media of A549 cells after exposure to the PAR 2 activator SLIGRL-NH 2 (F) or to the partially scrambled control peptide LSIGRL-NH 2 (E). A, in time course studies, cells were exposed to 25 M SLIGRL-NH 2 or LSIGRL-NH 2 for selected periods of time (15 min-24 h). B, in concentration-response studies, cells were exposed to selected concentrations of SLIGRL-NH 2 or LSIGRL-NH 2 (1-100 M) for 24 h. SLIGRL-NH 2 -induced increases in PGE 2 levels were also measured in the presence of a cyclooxygenase inhibitor indomethacin (2 M, OE). Shown are the mean levels of PGE 2 Ϯ S.E.M., expressed in terms of picograms per 100,000 cells. Fig. 2 . PGE 2 levels in the media of A549 cells after a 30-min exposure to 50 M SLIGRL-NH 2 (black columns) or sterile saline (white column). A549 cells were pretreated for 24 h with combinations of 10 g/ml LPS and 1 M dexamethasone (or vehicles, as indicated), and washed thoroughly before the 30-min exposure period with SLIGRL-NH 2 or sterile saline. Shown are the mean levels of PGE 2 Ϯ S.E.M., expressed in terms of picograms per 100,000 cells.
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at ASPET Journals on October 18, 2017 jpet.aspetjournals.org Downloaded from 1997; Chivers et al., 2004) . In these epithelial cell cultures, glucocorticoids inhibit PGE 2 production by suppressing the release of arachidonic acid, an initial substrate in the synthesis of PGE 2 (Chivers et al., 2004) , and by inhibiting the expression of PGES and COX, which convert arachidonic acid into PGE 2 (Mitchell et al., 1994; Newton et al., 1997; Chivers et al., 2004) . In addition, glucocorticoids enhance the metabolism of PGE 2 by increasing the expression of prostaglandin dehydrogenase (Tong and Tai, 2005) . This raises the possibility that glucocorticoids will suppress the activity of substances, such as PAR 2 activators, whose bronchoprotective actions are predominantly mediated via the production of PGE 2 (Cocks et al., 1999; Lan et al., 2001; De Campo and Henry, 2005) . Consistent with this postulate, we observed that PAR 2 -mediated, SLIGRL-NH 2 -induced increases in PGE 2 levels in airway epithelial cell cultures were abolished by the glucocorticoid, dexamethasone. However, despite these impressive inhibitory effects in cultured cells, dexamethasone did not inhibit relaxation responses induced by SLIGRL-NH 2 in intact airway smooth muscle preparations, irrespective of whether the responses were obtained after short-term in vitro exposure, long-term in vitro exposure, or in vivo exposure to dexamethasone. Furthermore, dexamethasone significantly enhanced the inhibitory effect of another PAR 2 -activating peptide f-LIGRL-NH 2 on lipopolysaccharide-induced neutrophilia in mice. Thus, although dexamethasone blocked PAR 2 -mediated effects in cultured epithelial cells, these inhibitory effects did not seem to be translated through to more complex biological systems.
In the current study, addition of SLIGRL-NH 2 to the culture medium of unstimulated A549 cells produced time-and concentration-dependent increases in PGE 2 levels. PGE 2 was produced rapidly, with half-maximal levels of PGE 2 obtained within 15 min of exposure to SLIGRL-NH 2 . Consistent with this, Kawao et al. (2005) recently demonstrated a time and concentration dependence of SLIGRL-NH 2 -induced PGE 2 production in A549 cells. Furthermore, a putative activator of PAR 2 neutrophil elastase also stimulated the rapid release of PGE 2 from primary cultures of human bronchial epithelial cells (Perng et al., 2003) . These rapid responses indicate that A549 cells constitutively express the signaling pathways required for PAR 2 -mediated production of PGE 2 . SLIGRL-NH 2 -induced production of PGE 2 in A549 cells seemed to be mediated via PAR 2 because the partially scrambled peptide LSIGRL-NH 2 was inactive (current study; Asokananthan et al., 2002; Kawao et al., 2005) .
Initial events in PAR 2 -mediated generation of PGE 2 include the activation of mitogen-activated protein kinase and 
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at ASPET Journals on October 18, 2017 jpet.aspetjournals.org cytosolic phospholipase A 2 and the resultant generation of arachidonic acid (Kawao et al., 2005) . Of particular relevance, dexamethasone has been reported to rapidly inhibit arachidonic acid (and hence PGE 2 ) release by inhibiting key components in the signal transduction pathway that lead to the activation of mitogen-activated protein kinase and cytosolic phospholipase A 2 Chivers et al., 2004) . Indeed, in the current study, pretreatment with dexamethasone significantly suppressed the levels of PGE 2 produced by A549 cells in response to short periods of PAR 2 activation by SLIGRL-NH 2 . Additional studies are required to identify the underlying mechanisms through which dexamethasone blocks PAR 2 -mediated increases in PGE 2 levels in cultured epithelial cells.
Airway epithelial cell cultures exposed to proinflammatory stimuli, including lipopolysaccharide, interleukin-1␤, and tumor necrosis factor-␣, release large amounts of PGE 2 into the surrounding media (Mitchell et al., 1994; Newton et al., 1998 Newton et al., , 2002 Rodgers et al., 2002; Petrovic et al., 2006 ). In the current study, SLIGRL-NH 2 -induced increases in PGE 2 levels were augmented in A549 cells previously exposed to lipopolysaccharide. These findings are consistent with the synergistic effects produced by the cytokine interleukin-1␤ and bradykinin on PGE 2 levels in epithelial cell cultures (Saunders et al., 1999; Newton et al., 2002) . Together, these findings support the postulate that concomitant activation of extracellular signal-regulated kinase (in the current study via PAR 2 ; Kawao et al., 2005) and induction of COX-2 by lipopolysaccharide stimulates maximum PGE 2 synthesis in human airway epithelial cells (Petrovic et al., 2006) . These synergistic effects of SLIGRL-NH 2 and lipopolysaccharide on PGE 2 production were not observed in cells cotreated with dexamethasone, probably due to the well documented inhibitory actions of glucocorticoids on cytokine-induced expression of important components of the PGE 2 synthetic pathway, including COX-2 (Mitchell et al., 1994; Aksoy et al., 1999; Chivers et al., 2006) . PAR 2 -activating peptides such as SLIGRL-NH 2 also stimulate the release of PGE 2 in intact airway preparations such as the mouse trachea (Lan et al., 2001; Henry et al., 2005) . PAR 2 -mediated release of PGE 2 from mouse trachea induces a marked smooth muscle relaxation response (Cocks et al., 1999; Lan et al., 2000 Lan et al., , 2001 Kawabata et al., 2004a ). In the current study, acute dexamethasone exposure did not inhibit SLIGRL-NH 2 -induced relaxation responses in mouse isolated tracheal preparations. Thus, although dexamethasone can, within minutes, inhibit key components in the signal transduction pathway leading to PGE 2 synthesis in cell culture systems Croxtall et al., 2000 Croxtall et al., , 2002 Chivers et al., 2004) , this effect was not evident in the intact airway preparations. In further studies, a tissue culture system was used to determine whether longer term in vitro exposure to dexamethasone altered the responsiveness of intact airway preparations to the PGE 2 -dependent relaxant actions of PAR 2 -activating peptides (Bachar et al., 2005) . In these studies, mouse isolated tracheal preparations exposed for 3 days to dexamethasone were no more or less sensitive to SLIGRL-NH 2 or PGE 2 than untreated preparations. Likewise, in vivo administration of dexamethasone to mice did not alter the in vitro sensitivity of tracheal preparations to either SLIGRL-NH 2 or PGE 2 . Thus, neither shortterm nor longer term in vitro exposure to dexamethasone, nor in vivo exposure to dexamethasone, had any significant inhibitory effect on the bronchodilatory PAR 2 -PGE 2 -EP 2 receptor axis in mouse isolated trachea.
In the current study, dexamethasone blocked PAR 2 -mediated production of PGE 2 in A549 cells but did not exert any inhibitory effect on PAR 2 -mediated relaxations in mouse isolated tracheal preparations. One possible explanation for these differential effects of dexamethasone is that PGE 2 synthesis was mediated by dexamethasone-sensitive COX-2 in A549 cells, whereas the relaxations of the murine tracheal smooth muscle were mediated by dexamethasone-insensitive COX-1. However, several comprehensive studies have demonstrated that PAR 2 -mediated production of PGE 2 by A549 cells (Kawao et al., 2005) and PAR 2 -mediated relaxation in mouse isolated tracheal segments (Kawabata et al., 2004) are mediated by both COX-1 and COX-2. Thus, it is unlikely that the current findings can be explained on the basis of dexa- Fig. 7 . Influence of f-LIGRL-NH 2 (A) and PGE 2 (B) on the numbers of neutrophils recovered from the BAL fluid of mice exposed to LPS and/or dexamethasone. Mice were pretreated for 3 days with daily injections of dexamethasone (1 mg/kg or cyclodextrin vehicle i.p.) and then inoculated intranasally with a 20-l solution containing combinations of lipopolysaccharide (10 g); a PAR 2 -activating peptide, f-LIGRL-NH 2 (30 g); and PGE 2 (10 g). BALs were performed 3 h after intranasal inoculations. Shown are the mean Ϯ S.E.M. responses obtained from six to nine mice per group. methasone selectively suppressing the expression/function of COX-2 because COX-2 is involved in PAR 2 -mediated relaxation of mouse isolated tracheal preparations (Lan et al., 2001; Kawabata et al., 2004) , and COX-1 is involved in PAR 2 -mediated generation of PGE 2 in A549 cells (Kawao et al., 2005) .
A major focus of the tension recording studies described above was to determine the influence of dexamethasone on relaxation responses induced by a PAR 2 -activating peptide SLIGRL-NH 2 . Concurrent experiments examined the effect of dexamethasone on relaxations induced by exogenous PGE 2 . These data indicate that neither in vivo nor in vitro exposure of trachea to dexamethasone inhibited the PGE 2 -EP receptor-relaxation pathway. Furthermore, we determined the influence of dexamethasone on carbachol concentration-response curves. The consistent finding that dexamethasone had no significant modulatory influence on carbachol-induced contractions was important because both the potency of, and maximum response to, bronchorelaxant agents such as SLIGRL-NH 2 and PGE 2 will be sensitive to changes in the level of spasmogen-induced tone.
In vivo administration of SLIGRL-NH 2 inhibits lipopolysaccharide-induced infiltration of neutrophils into the lungs of BALB/c mice (Moffatt et al., 2002 ). In the current study, a similar inhibitory response was produced by f-LI-GRL-NH 2 , a structurally related PAR 2 -activating peptide. f-LIGRL-NH 2 was used in these latter experiments because it is a more potent and metabolically stable PAR 2 -activating peptide than SLIGRL-NH 2 (Kawabata et al., 2004b) , and thus better suited to in vivo studies. Additional studies were conducted to determine whether f-LIGRL-NH 2 -induced inhibition of neutrophil infiltration was modulated by cotreatment with the glucocorticoid dexamethasone. In these studies, pretreatment of lipopolysaccharide-exposed mice with dexamethasone alone was associated with reduced BAL neutrophil numbers, as previously demonstrated by others (Lefort et al., 2001; Birrell et al., 2004; Kang et al., 2006; Moschos et al., 2007) . Of particular interest, the inhibitory effect of f-LIGRL-NH 2 on neutrophil infiltration in lipopolysaccharide-exposed mice was significantly greater in mice that were cotreated with dexamethasone. Consistent with a previous report (Goncalves de Moraes et al., 1996) , intranasal PGE 2 significantly reduced BAL neutrophil numbers in lipopolysaccharide-exposed mice. Moreover, this effect was further enhanced by dexamethasone cotreatment. The underlying mechanism for this interaction among lipopolysaccharide, glucocorticoids, and PGE 2 (exogenous or PAR 2 -mediated) is not clear, although recent evidence implicates the transcription factor NF-B as a pivotal player in this process. For example, NF-B plays an important role in lipopolysaccharide-induced inflammatory responses (for review, see Doyle and O'Neill, 2006) , and the level of activation of NF-B in lipopolysaccharide-exposed cells has been reported to be suppressed by both glucocorticoids (Eddleston et al., 2007; Newton and Holden, 2007) and PGE 2 (Gomez et al., 2005) . Regardless of whether this represents an additive or synergistic effect between the PAR 2 -activating peptide/PGE 2 and the glucocorticoid, it was clear that their combined effects were altogether greater than their individual activities, and there was no indication that the anti-inflammatory actions of f-LIGRL-NH 2 or PGE 2 were at all suppressed by dexamethasone. On a side note, although PAR 2 -activating peptides have been reported to increase the numbers of neutrophils in control mice (Su et al., 2005) , there was no indication in the current study that intranasal f-LIGRL-NH 2 produced any significant increase in BAL neutrophil numbers above that produced by vehicle in mice that were not exposed to lipopolysaccharide.
In summary, the current study clearly demonstrates that dexamethasone does not inhibit PAR 2 -dependent, PGE 2 -mediated relaxation responses in murine airways and, to the contrary, may augment anti-inflammatory responses to PAR 2 -activating peptides in the lipopolysaccharide-exposed lung. Thus, agents that elevate endogenous levels of PGE 2 and/or stimulate downstream EP receptors are likely to retain their bronchoprotective activity in the presence of coadministered glucocorticoid pharmacotherapy.
